Did narcolepsy occur following administration of As03- adjuvanted A(H1N1) pandemic vaccine in Ontario, Canada? A review of post-marketing safety surveillance data

Eurosurveillance

Volumn 19, Issue 36, 2014, Pages 1-5

  Harris, T ^a   Wong, K ^a   Stanford, L ^b   Fediurek, J ^a   Crowcroft, N ^a,c,d   Deeks, S L ^a,c  

^a PUBLIC HEALTH ONTARIO   (Canada)

^b Simcoe Muskoka District Health Unit Ontario   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANADA; CHILD; CLINICAL ARTICLE; DRUG SAFETY; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; MEDICAL RECORD REVIEW; NARCOLEPSY; POSTMARKETING SURVEILLANCE; SYMPTOM;

EID: 84907755464     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.es2014.19.36.20900     Document Type: Article

References (27)

1. International classification of sleep disorders. Diagnostic and coding manual. 2nd ed. Westchester: American Academy of Sleep Medicine; 2005.
2. Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep. 2007;30(1):13-26.
3. Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted county, Minnesota: A populationbased study. Sleep. 2002;25(2):197-202.
4. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One. 2012;7(3):e33536. http://dx.doi.org/10.1371/journal.pone.0033536
5. Committee for Medicinal Products for Human Use (CHMP). Assessment report. Pandemrix. London: European Medicines Agency; 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000832/WC500118056.pdf
6. Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations - Results of a case inventory study by the MPA in Sweden during 2009-2010. Uppsala: Swedish Medical Products Agency; 2011. Available from: http://www.lakemedelsverket.se/upload/nyheter/2011/Fallinventeringsrapport_pandermrix_110630.pdf
7. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, Hublin C, Linna M, Olsen P, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One. 2012;7(3):e33723. http://dx.doi.org/10.1371/journal.pone.0033723
8. Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in Western Sweden after H1N1 influenza vaccination. Neurology. 2013;80(14):1315-21. http://dx.doi.org/10.1212/WNL.0b013e31828ab26f
9. Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, et al. The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine. 2013;31(8):1246-54. http://dx.doi.org/10.1016/j.vaccine.2012.12.015
10. Global Advisory Committee on Vaccine Safety, December 2012. Wkly Epidemiol Rec. 2013;88(6):65-72.
11. Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: Retrospective analysis. BMJ. 2013;346:f794. http://dx.doi.org/10.1136/bmj.f794
12. Global Advisory Committee on Vaccine Safety, 12-13 June 2013. Wkly Epidemiol Rec. 2013;88(29):301-12.
13. Lessons learned review. Public Health Agency of Canada and Health Canada response to the 2009 H1N1 pandemic. Ottawa: Public Health Agency of Canada; 2010. Available from: http:// www.phac-aspc.gc.ca/about_apropos/evaluation/reportsrapports/ 2010-2011/h1n1/index-eng.php
14. Assessment report immunological differences of pandemic vaccines (review of hypothesis on Pandemrix and development of narcolepsy). Review Under Article 5(3) of Regulation (EC) no 726/2004. London: European Medicines Agency; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/11/WC500134716.pdf
15. Dauvilliers Y, Montplaisir J, Cochen V, Desautels A, Einen M, Lin L, et al. Post-H1N1 narcolepsy-cataplexy. Sleep. 2010;33(11):1428-30.
16. Risk of narcolepsy associated with administration of inactivated adjuvanted (AS03) A/H1N1 pandemic influenza vaccine in Quebec. Bethesda: National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/ NCT01394614
17. Infectious Diseases Protocol, 2009. Appendix B: Provincial case definitions for reportable diseases. Disease: Adverse Events Following Immunization (AEFIs) [archived]. Toronto: Ministry of Health and Long-Term Care; 2009.
18. Akintomide GS, Rickards H. Narcolepsy: A review. Neuropsychiatr Dis Treat. 2011;7:507-18. http://dx.doi.org/10.2147/NDT.S23624
19. th Meeting of the Eurpoean Society of Paediatric Infectious Diseases. 7-11 June, 2011; The Hague, The Netherlands.
20. Annual report on vaccine safety in Ontario, 2012. Toronto: Queen’s Printer for Ontario; 2014. Available from: http://www.publichealthontario.ca/en/BrowseByTopic/InfectiousDiseases/ Pages/Vaccine-Safety.aspx
21. Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun MM, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J. 2004;23(4):287-94. http://dx.doi.org/10.1097/00006454-200404000-00002
22. Poli F, Overeem S, Lammers GJ, Plazzi G, Lecendreux M, Bassetti CL, et al. Narcolepsy as an adverse event following immunization: Case definition and guidelines for data collection, analysis and presentation. Vaccine. 2013;31(6):994-1007. http://dx.doi.org/10.1016/j.vaccine.2012.12.014
23. Iskander J, Pool V, Zhou W, English-Bullard R, VAERS Team. Data mining in the US using the Vaccine Adverse Event Reporting System. Drug Saf. 2006;29(5):375-84. http://dx.doi.org/10.2165/00002018-200629050-00002
24. Botsis T, Nguyen MD, Woo EJ, Markatou M, Ball R. Text mining for the Vaccine Adverse Event Reporting System: Medical text classification using informative feature selection. J Am Med Inform Assoc. 2011;18(5):631-8. http://dx.doi.org/10.1136/amiajnl-2010-000022
25. Tolentino HD, Matters MD, Walop W, Law B, Tong W, Liu F, et al. A UMLS-based spell checker for natural language processing in vaccine safety. BMC Med Inform Decis Mak. 2007 12;7:3.
26. Brighton Collaboration. Annual Report 2012. [Internet]. Basel: Brighton Collaboration; 2013. Available from: https://brightoncollaboration.org/public/who-we-are/annual-report/ extras/02/link/Audit%20Report%20FER%20(with%202%20 signatures).pdf
27. Dauvilliers Y, Arnulf I, Lecendreux M, Monaca Charley C, Franco P, Drouot X, et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain. 2013;136(Pt 8):2486-96.http://dx.doi.org/10.1093/brain/ awt187